Aktuellt
SENASTE
Ahead of the Q2 report, we make minor cuts to our 2021-23 adj. EBIT by 0-3%. Whilst we believe the pandemic is likely to have weighed somewhat on demand also for Q2, Bactiguard remains favourably positioned to deliver on growth opportunities ahead. For now, the rollout of ZNN Bactiguard implants and potential new licence agreements will catch investors’ attention and together constitutes the major triggers throughout 2021, we believe.
LÄS MER
